Meningitis
Global mortality data, country rankings, and trends for Meningitis from 1990 to 2021.
| # | Country | Share (%) | Region |
|---|
Meningitis is a significant contributor to the global burden of disease. This page presents data from the Institute for Health Metrics and Evaluation (IHME) Global Burden of Disease Study, showing mortality trends, country rankings, and regional patterns. Understanding the epidemiology of meningitis helps inform public health interventions and resource allocation.
This data is sourced from the Institute for Health Metrics and Evaluation (IHME) Global Burden of Disease Study 2023, processed via Our World in Data. Values represent each cause's share of total deaths (%) unless otherwise noted. Explore related mortality data using the links below.
Meningitis — inflammation of the membranes surrounding the brain and spinal cord — kills approximately 250,000 people annually and leaves one in five survivors with long-term disabilities including hearing loss, epilepsy, and cognitive impairment. Bacterial meningitis (Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae) is the most lethal form, with case fatality rates of 20-50% even with treatment. The 'meningitis belt' of sub-Saharan Africa — stretching from Senegal to Ethiopia — experiences periodic devastating epidemics of meningococcal disease. Neonatal meningitis, caused by Group B streptococcus and E. coli, is a significant cause of death and disability in newborns. Tuberculous and cryptococcal meningitis affect immunocompromised individuals, particularly those living with HIV. Overcrowded living conditions, poverty, and dry dusty climates are environmental risk factors. The WHO has launched a global roadmap to defeat meningitis by 2030, aiming for 50% reduction in cases and 70% reduction in deaths.
Across 210 countries, meningitis accounts for an average of 0.5% of total deaths. Regional disparities are substantial: Sub-Saharan Africa has the highest regional average at 1.6%, while North America records the lowest at 0.0% — a 47.1-fold difference that underscores the geographic inequality in meningitis mortality burden.
Conjugate vaccines against meningococcal serogroups (A, C, W, Y), pneumococcal disease, and Hib have dramatically reduced bacterial meningitis incidence where deployed. The MenAfriVac conjugate vaccine virtually eliminated serogroup A epidemics across the African meningitis belt after mass campaigns. Pentavalent meningococcal conjugate vaccines offer broader protection. Rapid epidemic detection and response systems, chemoprophylaxis for close contacts, and improved diagnostic capacity at district hospital level are essential public health measures.